Literature DB >> 11173629

The Dominant T-Helper Lymphocyte Function of HIV Infected Patients.

András Falus, Károly Nagy, Erzsébet Temesvári, Attila Horváth.   

Abstract

In HIV infection, the decrease in the number and functional activity of lymphocytes is accompanied by atopia and an increased level of total IgE and some specific IgE antibodies. This could be explained by the Th2 dominance induced by HIV replication and so a Th1-Th2 switch could have prognostic value. We investigated the characteristic T-helper phenotype dominance and its relationship to cytokine expression and IgE immune response in the early stage of asymptomatic HIV infection. In the separated lymphocytes of i. asymptomatic HIV positive persons; ii. HIV negative homosexuals; iii. atopic patients; and iv. healthy controls, expression of mRNA for IFNg (Th1) and IL-10 (Th2) were determined by semiquantitative RT-PCR. The serum level of antibodies for HIV 1/2 and total/specific IgE were also determined. Transcription of mRNA of IFNg and IL-10 were more pronounced in HIV positive and atopic groups than in the healthy control, without lymphocyte phenotype dominance. In HIV negative persons, however, a significant Th2 dominance was detected. There was no significant difference in the IgE level between the 4 investigated groups. In the HIV positive cases, IL-10 expression and total serum IgE do not support a switch to Th2 dominance. In the atopic group, aside from the total IgE level, down regulation of IFNg was not observed. These results suggest a general activation of the immune system in the early stage of HIV infection.

Entities:  

Year:  1997        PMID: 11173629     DOI: 10.1007/bf02893357

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  28 in total

1.  Total and specific IgE in sera of HIV positive and HIV negative homosexual male (regulation of IgE synthesis in HIV infection).

Authors:  A Horváth
Journal:  Acta Biomed Ateneo Parmense       Date:  1992

Review 2.  Type 1 and type 2: a fundamental dichotomy for all T-cell subsets.

Authors:  L L Carter; R W Dutton
Journal:  Curr Opin Immunol       Date:  1996-06       Impact factor: 7.486

3.  Serum total and specific IgE levels in children infected with human immunodeficiency virus.

Authors:  A Koutsonikolis; R P Nelson; E Fernandez-Caldas; E N Brigino; M Seleznick; R A Good; R F Lockey
Journal:  J Allergy Clin Immunol       Date:  1996-02       Impact factor: 10.793

4.  Elevation of IgE in HIV-infected children and its correlation with the progression of disease.

Authors:  A Viganó; N Principi; L Crupi; J Onorato; Z G Vincenzo; A Salvaggio
Journal:  J Allergy Clin Immunol       Date:  1995-02       Impact factor: 10.793

5.  Evidence for a shift from a type I lymphocyte pattern with HIV disease progression. Hemophilia Growth and Development Study.

Authors:  J Jason; L A Sleeper; S M Donfield; J Murphy; I Warrier; S Arkin; B Evatt
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-12-01

6.  IgE levels in pediatric HIV-1 infection.

Authors:  M Ellaurie; A Rubinstein; D L Rosenstreich
Journal:  Ann Allergy Asthma Immunol       Date:  1995-10       Impact factor: 6.347

Review 7.  Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy.

Authors:  G Del Prete
Journal:  Allergy       Date:  1992-10       Impact factor: 13.146

8.  Differences in IL-4 release by PBMC are related with heterogeneity of atopy.

Authors:  J Pène; A Rivier; B Lagier; W M Becker; F B Michel; J Bousquet
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

9.  Serum measurements of soluble CD23 in HIV infection.

Authors:  A S Bansal; R S Pumphrey; B K Mandal; S H Khoo; P B Wilson
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

10.  T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons.

Authors:  J Estaquier; T Idziorek; W Zou; D Emilie; C M Farber; J M Bourez; J C Ameisen
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.